Novel Blood Test Improves Cancer Treatment Strategies
University of Zurich and University Hospital Zurich have developed a novel blood test that revolutionizes cancer treatment strategies. The liquid biopsy method offers a less invasive and more practical approach to monitoring treatment effectiveness, providing valuable insights into tumor activity and spread. This personalized approach allows for tailored treatment plans, improved outcomes, and early detection of cancer recurrence.
Top Doctors Caution Against Expensive Multi-Cancer Detection Tests
Top doctors caution against expensive blood tests claiming to detect 50 types of cancer, urging regular screenings. Multi-cancer detection tests (MCDs) are gaining popularity as non-invasive alternatives, but experts warn of false positives and lack of insurance coverage. Recent updates to screening guidelines for colorectal and breast cancers align with the advice to proceed with caution. Dr. Chyke Doubeni from Ohio State University emphasizes the risks and lack of conclusive evidence supporting the efficacy of MCDs, despite some promising results from recent studies.
ScreenPoint Medical Deploys Transpara Breast AI at Johns Hopkins Medicine to Enhance Cancer Detection
ScreenPoint Medical’s Transpara Breast AI has been deployed at Johns Hopkins Medicine to improve cancer detection for breast cancer screening patients, benefiting radiologists and patients across 50 sites in 5 states and the District of Columbia. The decision to implement Transpara followed a thorough evaluation of the software’s evidence, effectiveness, and performance by the breast imaging team at Johns Hopkins. The aim is to enhance screening workflow, decision confidence, and breast cancer diagnostic assessment, ultimately aiding radiologists in the early detection of breast cancer and reducing recall rates.
Washington University School of Medicine Joins National Clinical Trials Network for Cancer Screening
Washington University School of Medicine in St. Louis has joined a new national clinical trials network launched by the National Cancer Institute (NCI) to investigate emerging technologies for cancer screening. The goal of the network is to reduce cancer-related illnesses and deaths, with a key priority being the inclusion of participants from diverse populations. Collaborating with Siteman Cancer Center, the investigators will lead trials in Missouri and parts of Illinois, aiming to reach diverse populations, including those living in underserved areas. The network’s primary focus is to evaluate the effectiveness of a screening technology designed to detect multiple cancers with a single blood test, with the researchers aiming to determine whether such tests can detect cancer early and ultimately save lives.
Study Shows Incarceration History Linked to Worse Access to Health Care
A recent study published in JAMA Health Forum found that individuals with a history of incarceration have worse access to and receipt of health care. The study revealed that these individuals had lower percentages of receiving preventive services, such as physical examinations, blood pressure tests, and cancer screenings. The findings emphasize the need for efforts to improve access to education and health insurance coverage for individuals with a history of incarceration in order to mitigate disparities in care.
Take Advantage of Cancer Screening
Learn about the importance of cancer screening and the most common cancers diagnosed in the Central Coast Local Health District. Find out how to reduce cancer risk and take advantage of available screening programs.
DELFI Diagnostics Announces Availability of Fragmentome-Based Cancer Monitoring Assay and Collaboration with Immunocore Holdings plc
DELFI Diagnostics, Inc. has announced the availability of the company’s fragmentome-based research use only (RUO) cancer monitoring assay, offering a highly sensitive, inexpensive means of noninvasive measurement of tumor burden and assessing treatment response and resistance in patients with advanced cancer. The company has also revealed a new research collaboration with Immunocore Holdings plc, focusing on exploring the use of the DELFI-TF cancer monitoring assay as an early predictor of benefit from treatment with ImmTAC-based therapies. DELFI Diagnostics is developing next-generation, blood-based tests that are accurate, accessible and deliver a new way to help detect cancer.
Cambridge Researchers Initiate Groundbreaking Clinical Trial for Capsule Sponge in Oesophageal Cancer Prevention
Oesophageal cancer is a significant health concern, and researchers at Cambridge have initiated a groundbreaking clinical trial to investigate the effectiveness of a ‘capsule sponge’ in preventing this type of cancer. The trial, named BEST4, is set to commence at…